• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

DNDi, Mundo Sano and Chemo team up to register benznidazole in US and Latin America

Plans will boost access to Chagas treatment throughout Americas

Rio de Janeiro, Brazil — 8 Jun 2016
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

In a bid to overturn a situation where less than 1% of people with Chagas disease have access to treatment, non-profit drug development organisation Drugs for Neglected Diseases initiative (DNDi), pharmaceutical company Chemo Group and non-profit foundation Mundo Sano are entering into a formal collaboration to boost affordable access to benznidazole, by registering this essential medicine in countries affected by this deadly disease, including the US. If Chemo obtains a priority review voucher from the FDA, the company commits to dedicate half of the proceeds to actions that benefit Chagas patients.
[Español] [Português]

Chemo Group and its corporate social responsibility partner Mundo Sano are working to register adult (100mg) and paediatric (12.5mg) benznidazole (BZN) for Chagas treatment with the US Food and Drug Administration (FDA), as well as in Mexico, Colombia and other endemic countries in Latin America. DNDi will support this move, by sharing with Chemo Group technical and scientific expertise, as well as by providing the data gathered with partners from previous clinical trials for adult and paediatric forms.

“Our ambition is to put an end to a scandalous and unjustifiable situation where almost none of the people living with Chagas has access to existing treatments,” said Dr Bernard Pécoul, DNDi Executive Director. “Registering benznidazole with the FDA will allow us to overcome the difficulties US patients have in accessing the drug, and will facilitate the registration process for the rest of the Americas.”

As a part of the agreement, Chemo Group commits to ensuring BZN is available to the public sector in Chagas-endemic countries on an affordable basis – at a price that covers manufacturing and distribution costs plus a reasonable margin.

“Our goal is to ensure its widespread use and equitable access for all patients”, said Leandro Sigman, Chemo Group Managing Director.

“There are many barriers to Chagas treatment, but the first one to overcome is the lack of access to the prescription drug,” said Silvia Gold, President of Mundo Sano. “We are proud to have Chemo Group as a reliable industrial partner capable of scaling up quality affordable benznidazole. Our hope is to transform the dynamic of access to treatment for Chagas patients throughout the Americas.”

To help address this situation, this agreement commits DNDi and Mundo Sano to developing an ambitious access plan in collaboration with stakeholders and partners, with a view to boosting demand by national programmes for BZN, strengthening demand forecasting, as well as communication campaigns to raise awareness and stimulate adoption.

By registering BZN with the US FDA, Chemo Group may qualify for a priority review voucher (PRV), a mechanism designed to encourage R&D into neglected diseases by awarding a voucher that fast-tracks FDA registration for another product. If Chemo Group obtains a PRV, the DNDi/Mundo Sano/Chemo agreement stipulates that Mundo Sano would receive 50% of any PRV-related financing to support its non-profit activities. DNDi and Mundo Sano would manage jointly half of those funds, to be dedicated to actions that benefit patients and encourage access, by supporting not-for-profit programmes to scale up diagnosis and treatment for Chagas disease.

“Our company is based on values shared with Mundo Sano. Chemo is a group that aims to sustain and improve people’s health, but also facilitate access to pharmacological treatments. Given the alarming lack of access to Chagas medicines, we are very proud to announce our commitment to dedicate 50% of an eventual economic advantage from the PRV to helping people living with this neglected disease”, said Leandro Sigman.

“Even if an affordable treatment is available, getting patients on treatment involves many complex concerted actions, from overcoming production challenges to boosting health system uptake and seeking patients’ support,” said Dr Joël Keravec, Regional Executive Director, DNDi Latin America. “The challenge will be to capitalize on the valuable efforts underway to boost diagnosis and treatment in countries such as Colombia, Bolivia, Brazil and the US, and develop a far-reaching access plan for Chagas disease in collaboration with governments, service providers and communities.”

The agreement builds on existing collaboration between DNDi and Mundo Sano to increase access to Chagas treatment. In 2013, DNDi joined forces with Mundo Sano to secure a second quality-assured source of BZN for children. DNDi has also been providing supporting to Chemo Group’s registration of BZN in Mexico and Colombia. This new collaboration extends registration plans to other endemic countries in the region.

Media Contacts

Chemo: comunicacion@chemogroup.net

DNDi (Latin America): Betina Moura / +55-21-98122-2798 / bmoura@dndi.org

DNDi (US): Ilan Moss / +1-646-266-5216 / imoss@dndi.org

Notes

ABOUT CHAGAS DISEASE

The leading parasitic killer of the Americas, Chagas disease (American trypanosomiasis) infects an estimated 8 million people, mostly in Latin America, where it is endemic in 21 countries and kills some 12,000 people each year. The most affected people are very poor, live in inadequate housing conditions, and often have little access to healthcare. Cases of Chagas disease are increasingly recognized in North America, Europe, Japan, and Australia. Caused by the parasite Trypanosoma cruzi, Chagas disease starts with an early, acute stage lasting about two months, and is followed by a late, chronic stage lasting a lifetime, in which up to 30% of patients develop life-threatening heart damage and up to 10% may have severe damage to their digestive system. Current treatments are still difficult to implement due to the duration of treatment and side effects associated with their use.

 

ABOUT DNDi

A not-for-profit R&D organization, DNDi works to deliver new treatments for neglected diseases, in particular leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, paediatric HIV, mycetoma, and hepatitis C. DNDi is actively engaged in developing new treatments and screening new compounds for Chagas disease. DNDi and partners delivered the first paediatric dosage form of benznidazole and is running clinical trials evaluating new regimens or combinations of the drug. DNDi is also involved in early stage research for entirely new drugs for Chagas disease.
www.dndi.org

ABOUT CHEMO GROUP

Chemo is a multinational pharmaceutical company with almost four decades of experience and commitment in safeguarding and improving people’s health and well-being. As a comprehensive health sciences group, Chemo operates in all areas of the chemical/pharmaceutical industry and specialises in the research, development, manufacturing, sales and marketing of pharmaceutical active ingredients and medicinal products for human and veterinary use. Chemo’s activities are organised into three synergistic business areas: Industrial, Branding and Biotechnology. The group has offices in more than 40 countries in Europe, America, Asia and Africa and has more than 5,000 professionals, 15 factories, 10 R&D centres and 33 affiliated pharmaceutical companies that provide services to more than 1,150 customers in 96 countries around the world. Chemo fulfils its social responsibilities through Mundo Sano, a non-profit foundation whose vision is the transformation of the realities of the populations affected by neglected diseases.
www.chemogroup.com

 

ABOUT MUNDO SANO

Mundo Sano is a civil society organization that since 1993 aims to reduce the impact caused by neglected diseases, such as Chagas disease, dengue, and various geoparasitosis, among others. In pursuit of achieving greater equity, the institution works alongside the public and private sectors, academia and other international organizations. In order to provide solutions to the affected communities and generate scientific knowledge, Mundo Sano led a public-private consortium in 2012 to produce benznidazole in Argentina, one of the main drugs to treat Chagas disease.
www.mundosano.org

Policy advocacy Partnership Chagas disease

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo